Merck & Co Inc at Leerink Partners Global Biopharma Conference Transcript

Mar 11, 2024 / 04:40PM GMT
Daina Michelle Graybosch - Leerink Partners LLC, Research Division - Senior MD of Immuno-Oncology and Senior Research Analyst

Hi, everyone. Thank you for coming to the session. My name is Daina Graybosch. I and my team cover immuno-oncology and beyond here at Leerink Partners. And I'm really excited to have a great oncology conversation with Merck. We have Dr. Marjorie Green and Peter Dannenbaum here.

And I thought maybe we'd start. Dr. Green, you could give a bit of an intro to yourself because you're relatively new to Merck, and then we'll jump into some questions on oncology and Merck.

Marjorie C. Green - Merck & Co., Inc. - Senior VP & Head of Late-Stage Oncology - Global Clinical Development

Fantastic. Thanks, Daina. Really excited to be here and for the opportunity. So I have joined Merck in April of 2023. By training, I am a breast medical oncologist, so I'm a sub-subspecialist and was at MD Anderson for a long time on faculty there and then moved to industry and have had the pleasure to work at Genentech and then most recently at Seagen

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot